GLP-1 Dosing and Titration: Why Slow Wins

Almost every GLP-1 medication comes with a stepwise dose-escalation schedule: you start low, hold for a few weeks, then move up, and repeat until you reach a maintenance dose. To an impatient new user it can look like cautious bureaucracy slowing down the results. It isn’t. The titration schedule is one of the most important parts of using these drugs well, and rushing it is the most common way people make themselves miserable.

Why you can’t just start at the top

The most common side effects of GLP-1s are gastrointestinal: nausea, reduced appetite, sometimes vomiting, constipation, or diarrhea. These effects are usually dose-related and tend to be worst when the dose changes. The body adapts over time, but it adapts gradually.

Slow titration is a trade: you accept a slower ramp to full effect in exchange for far better tolerability and a much lower chance of quitting over side effects.

Start at a high dose and you don’t get faster results; you usually get overwhelming nausea, a bad experience, and a higher likelihood of stopping the drug entirely. The escalation schedule exists to let your gut catch up to each new dose before the next increase.

What good titration looks like in practice

Wegovy (semaglutide 2.4 mg) is a clear illustration. Its official label escalates the once-weekly injection in defined four-week steps:

Weeks	Weekly dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg (maintenance)

So it takes about 16 weeks of stepwise increases to reach the full maintenance dose. The starting 0.25 mg is explicitly not a treatment dose: it exists only to let the gut begin adapting. The general logic across agents is consistent, even when the exact numbers differ:

• Begin at a low, often sub-therapeutic starting dose chosen mainly for tolerability rather than maximum effect.
• Hold each step for a defined period (commonly four weeks) before increasing.
• Only move up when the current dose is reasonably well tolerated. The Wegovy label itself states that if a patient doesn’t tolerate a dose during escalation, the clinician should consider delaying the next increase by four weeks.
• The maintenance dose is a range, not a finish line. Not everyone needs the maximum; the right dose is the lowest one that achieves the goal with acceptable side effects.

Personalizing the ramp

Titration schedules are templates, not commandments. Some people tolerate increases easily and move on schedule; others need to stay at a step longer, or even step back down temporarily. Slowing the ramp when side effects are rough is a legitimate, common adjustment, not a failure. The goal is sustainable use, not speed.

Side effects, in proportion

A few honest framings:

• The GI effects are usually most intense early and after each increase, then ease as the body adapts.
• Simple habits (smaller meals, eating more slowly, staying hydrated, easing off fatty or large meals) often blunt the worst of it.
• Persistent severe symptoms, or anything beyond ordinary GI upset, are a reason to contact a clinician rather than push through.

The takeaway

The titration schedule is the design feature that makes these medications usable, not an obstacle between you and results. The Wegovy label’s own instruction (delay the next increase if you don’t tolerate the current dose) captures the whole philosophy. Going slow doesn’t cost you the outcome; it protects your ability to stay on the drug long enough to get one. If a dose increase feels rough, the right move is almost always to hold or slow down and talk to your prescriber, not to tough it out or jump ahead. Patience here is the strategy, not a compromise.

Sources

• Wegovy (semaglutide) Dosing and Administration (NovoMedLink, Novo Nordisk)

This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.